Canopy Growth (CGC) Depreciation & Amortization (CF) (2019 - 2025)
Canopy Growth (CGC) reported Depreciation & Amortization (CF) of $10.2 million for Q4 2025, up 232.85% on a YoY basis from $3.1 million in Q4 2024, and up 234.92% sequentially from $3.1 million in Q3 2025.
Canopy Growth (CGC) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $10.2 million in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 232.85% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (up 61.39% YoY), and the FY2026 full-year result was $13.9 million, down 7.5% from the prior year.
- Depreciation & Amortization (CF) climbed to $10.2 million in Q4 2025, from $3.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $15.5 million in Q1 2022 to a low of $3.1 million in Q3 2025.
- A 5-year average of $7.6 million and a median of $8.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slumped 56.41% in 2023 and surged 232.85% in 2025, its largest moves.
- Tracing CGC's Depreciation & Amortization (CF) over 5 years: stood at $4.4 million in 2021, then jumped by 94.41% to $8.6 million in 2022, then tumbled by 56.28% to $3.7 million in 2023, then slipped by 17.72% to $3.1 million in 2024, then surged by 232.85% to $10.2 million in 2025.
- Business Quant data shows CGC's Depreciation & Amortization (CF) at $10.2 million in Q4 2025, $3.1 million in Q3 2025, and $3.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.24 Mn |
| Dec 31, 2025 | 10.24 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Dec 31, 2023 | 3.74 Mn |
| Dec 31, 2023 | 3.74 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 7.96 Mn |
| Jun 30, 2023 | 7.96 Mn |